Clinical Trial Update: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab as salvage therapy for plasma cell myeloma patients progressing after CAR-T therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Myeloma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Emory University | Conditions: Plasma Cell Myeloma | Phase 2 | Status: WITHDRAWN